

SWIXX AND BLUEPRINT MEDICINES ENTER INTO CEE + GREECE AGREEMENT FOR AYVAKYT® (avapritinib)

SWIXX ANNOUNCEMENT NO. 46

April 11th, 2022

Baar, Switzerland – Swixx BioPharma AG of Baar, Switzerland, announced today the signature of an Exclusive Distribution Agreement with Blueprint Medicines (Netherlands) BV of Amsterdam, a fully-owned subsidiary of Blueprint Medicines Corporation of Cambridge, Massachusetts. The contract calls for Swixx to commercialize Blueprint's Ayvakyt® (avapritinib) across the EEA countries of Central and Eastern Europe (including Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia and Slovenia), Greece, Cyprus, Malta and also the West Balkan non-EEA countries of Albania, Bosnia-Herzegovina, Kosovo, Montenegro, North Macedonia and Serbia.

Ayvakyt® (avapritinib) was approved in 2020 by the EMA for the treatment of unresectable or metastatic gastrointestinal stromal tumours (GISTs) harbouring a PDGFRA D842V mutation. Ayvakyt® was additionally approved by the EMA in March 2022 as a monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis (SM) with an associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL), after at least one systemic therapy.

"Ayvakyt® is a landmark precision medicine bringing new hope and relief to oncology – haematology patients in CEE who suffer from GIST or varying advanced forms of systemic mastocytosis" commented Dr. Dezso Martha, COO of Swixx. "All of us at Swixx are encouraged, and indeed grateful, to be given the opportunity to work with this breakthrough therapy in these rare haematology-oncology diseases. We do appreciate Blueprint's faith in Swixx, symbolized not least by the broad territory of twenty countries for which Blueprint has made Swixx responsible. We intend swiftly to justify Blueprint's confidence and look forward to work closely with Blueprint to rapidly increase access to Ayvakyt® for patients across CEE. On behalf of the Swixx team, let me thank our new friends at Blueprint in both Cambridge, Massachusetts and Zug, Switzerland."

About Swixx BioPharma AG

Swixx operates fully owned subsidiaries across Central and Eastern Europe, Greece, Russia and several Eurasian Economic Union countries plus Uzbekistan. With over 1000 employees and sales likely to exceed 600M Euros in 2022, Swixx has swiftly evolved into the largest and fastest-growing dedicated agent for biopharma and self-medication innovative companies in CEE. The company has gathered outstanding rare disease, oncology-haematology, specialty, and self-medication talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com

Contact: Vedrana Sokac Brataljenovic, Public Affairs Director, Swixx BioPharma A.G.

vedrana.sokac@swixxbiopharma.com Tel: +385 1 425 6086